- Home
- PPBI vs XENE Comparison
PPBI vs XENE Comparison
Compare PPBI & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBI
- XENE
- Stock Information
- Founded
- PPBI 1983
- XENE 1996
- Country
- PPBI United States
- XENE Canada
- Employees
- PPBI N/A
- XENE N/A
- Industry
- PPBI Major Banks
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- PPBI Finance
- XENE Health Care
- Exchange
- PPBI Nasdaq
- XENE Nasdaq
- Market Cap
- PPBI 2.2B
- XENE 2.4B
- IPO Year
- PPBI 1997
- XENE 2014
- Fundamental
- Price
- PPBI $22.57
- XENE $30.30
- Analyst Decision
- PPBI Buy
- XENE Strong Buy
- Analyst Count
- PPBI 4
- XENE 11
- Target Price
- PPBI $27.25
- XENE $54.82
- AVG Volume (30 Days)
- PPBI 1.2M
- XENE 1.4M
- Earning Date
- PPBI 07-24-2025
- XENE 08-07-2025
- Dividend Yield
- PPBI 5.96%
- XENE N/A
- EPS Growth
- PPBI N/A
- XENE N/A
- EPS
- PPBI 1.43
- XENE N/A
- Revenue
- PPBI $584,278,000.00
- XENE $7,500,000.00
- Revenue This Year
- PPBI N/A
- XENE N/A
- Revenue Next Year
- PPBI $6.74
- XENE $253.71
- P/E Ratio
- PPBI $15.55
- XENE N/A
- Revenue Growth
- PPBI 48.04
- XENE N/A
- 52 Week Low
- PPBI $18.06
- XENE $26.74
- 52 Week High
- PPBI $30.28
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- PPBI 56.38
- XENE 39.19
- Support Level
- PPBI $21.15
- XENE $30.84
- Resistance Level
- PPBI $22.41
- XENE $32.72
- Average True Range (ATR)
- PPBI 0.60
- XENE 1.07
- MACD
- PPBI -0.06
- XENE -0.19
- Stochastic Oscillator
- PPBI 70.65
- XENE 1.98
About PPBI Pacific Premier Bancorp Inc
Pacific Premier Bancorp Inc through its subsidiaries, provides banking products and services. It offers cash management, electronic banking services, credit facilities, and retirement accounts, among others.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.